Feedback PLC Adoption of TexRAD research software (6329K)
20 April 2015 - 8:00AM
UK Regulatory
TIDMFDBK
RNS Number : 6329K
Feedback PLC
20 April 2015
20 April 2015
Feedback plc
("Feedback", the "Company")
Adoption of TexRAD research software
Feedback plc (AIM: FDBK), the medical imaging software company,
is pleased to announce the adoption of its TexRAD research software
by four further leading cancer research institutions.
1) The Evangelische Lungenklinik Berlin (ELK)
ELK is an internationally recognisedspecialist hospital for
diseases of the chest treating more than 18,000 patients annually.
The sale of the TexRAD research software to the Radiology
Department at ELK is our first sale into Germany. This installation
will be used to evaluate lung cancer treatment outcomes, one of the
leading causes of cancer mortality and a key area of interest for
TexRAD.
2) Velindre Cancer Centre, Cardiff, Wales, UK
This first sale in Wales is an important milestone in the
development phase of TexRAD where the Company's software is being
used by clinical oncologists as a research tool in assessing tumour
heterogeneity as a way of monitoring the progression and response
of tumours to therapy.
3) University of Tokyo, Department of Radiology at the Institute of Medical Science
Japan has one of the highest numbers of CT and MRI scanners per
capita in the world. This leading research institute joins the
Company's growing list of adopters to use TexRAD software for
research purposes.
4) Centre Hospitalier Universitaire De Reims, Reims, France
This is the Company's first major hospital site outside Paris,
where it already has two prestigious sites as users. Here the
Company will be providing a customised laptop solution (rather than
the Company's standard server-based solution) demonstrating its
flexibility in meeting the specific requirements of clients.
These recent sales of TexRAD, together with others over the last
two months with a combined sales value of over GBP100,000, are a
further indication of the interest in TexRAD as a potentially
valuable quantitative tool in cancer research. The revenue
associated with these sales will be recognised over the life of the
12 month contracts in accordance with the Company's revenue
recognition accounting policy.
Tom Charlton, Director of Feedback plc, commented:
"We are delighted by the interest from leading centres of
oncology research in using our TexRAD texture analysis
software"
For further information contact:
Feedback plc Tel: 01954
718072
Simon Barrell / Trevor Brown
/ Tom Charlton
Sanlam Securities UK (Nominated Adviser and
Joint Broker)
Simon Clements / Virginia Bull Tel: 020 7628
2200
Peterhouse Corporate Finance Tel: 020 7469
Ltd (Joint Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD (is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
it is currently possible to see with the naked eye. Research to
date has shown that TexRAD could potentially assist the clinician
(as an 'Imaging-Biomarker') in confident decision-making: assessing
the prognosis, disease-severity (e.g. risk of metastases) and
response evaluation of patients with cancer. Currently TexRAD
research has shown great potential in many different oncological
sites, including, colorectal, breast, lung, prostate, oesophageal,
head & neck, lymphoma, liver and renal cancers and could
potentially be employed as a heterogeneity assessing tool in the
era of 'Precision and Personalized Medicine'.TexRAD is manufactured
under licence by the ISO 13485 certified company Cambridge Computed
Imaging Ltd, a subsidiary of Feedback plc. More information is
available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGGUGGCUPAGQM
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024